Smith+Nephew trading update for the quarter ended 26 September 2026.

Q3 Highlights

• Q3 revenue of $1,551 million (Q3 2025: $1,501 million), representing 3.4% revenue growth on both an underlying and reported basis (Q3: 63 trading days, in line with Q3 2025):
  • Strong Sports Medicine & ENT performance, including double-digit growth in Sports Medicine Joint Repair
  • Improved performance in Advanced Wound Management, led by acceleration in Devices
  • Orthopaedics returned to growth, despite soft market conditions and continued weak performance in US Hips and Knees
  • Double-digit growth in CATALYSTEM™, CONCELOC™, AETOS™, CORI™, REGENETEN™, Q-FIX™, FASTSEAL™, LEAF™ and PICO™
• Cementless LANDMARK™ Knee received 510(k) clearance, with first US surgical cases completed
• Completed first cases using TESSA™ Spatial Surgery System for femoral repair of the ACL, and submitted for regulatory approval for use in tibial tunnel placement

Full year guidance updated

• Revenue growth now expected to be around 3% on an underlying basis, reflecting our outlook for US Hips and Knees in the fourth quarter and market conditions
• Trading profit growth now expected to be around 4%, with trading profit around $1,250 million
• Free Cash Flow now expected to be around $750 million, with strong trading cash conversion of around 95%

RISE strategy progress

• Investing in higher growth and margin Sports Medicine and Advanced Wound Management businesses where we see a clear route to market leadership
• Continuing to focus on improving Orthopaedics performance as we successfully launch new products while we actively explore the full range of options to deliver value for stakeholders

Share buyback

• Previously announced $500m share buyback on track, with $250 million completed by the end of Q3, reflecting our continued strong cash flow and balance sheet

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.